

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BIIB | NASDAQ | USD | Real-time | |
BIIB | Mexico | MXN | Delayed | |
BIIB | Frankfurt | EUR | Delayed | |
BIIB | Xetra | EUR | Delayed | |
BIIB | TradeGate | EUR | Delayed | |
BIIB | Santiago | USD | Delayed | |
BIIB | Buenos Aires | ARS | Delayed | |
BIIB34 | BM&FBovespa | BRL | Delayed | |
BIIB | Vienna | EUR | Delayed |
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
Name | Age | Since | Title |
---|---|---|---|
Alexander John Denner | 52 | 2009 | Independent Director |
Michel Vounatsos | 59 | 2016 | CEO & Director |
Stelios Papadopoulos | 73 | 2008 | Independent Chairman of the Board |
Caroline D. Dorsa | 63 | 2010 | Independent Director |
Maria C. Freire | 68 | 2021 | Independent Director |
Stephen A. Sherwin | 73 | 2010 | Independent Director |
Richard C. Mulligan | 67 | 2009 | Independent Director |
Eric K. Rowinsky | 65 | 2010 | Independent Director |
William A. Hawkins | 68 | 2019 | Independent Director |
Jesus B. Mantas | 53 | 2019 | Independent Director |
William D. Jones | 66 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review